ENANTA PHARMACEUTICALS INC (ENTA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ENANTA PHARMACEUTICALS INC Do?
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. ENANTA PHARMACEUTICALS INC (ENTA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jay R. Luly and employs approximately 160 people, headquartered in WATERTOWN, Massachusetts. With a market capitalization of $376M, ENTA is one of the notable companies in the Healthcare sector.
ENANTA PHARMACEUTICALS INC (ENTA) Stock Rating — Reduce (April 2026)
As of April 2026, ENANTA PHARMACEUTICALS INC receives a Reduce rating with a composite score of 37.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ENTA ranks #3,007 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ENANTA PHARMACEUTICALS INC ranks #436 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ENTA Stock Price and 52-Week Range
ENANTA PHARMACEUTICALS INC (ENTA) currently trades at $14.11. The stock gained $0.16 (1.1%) in the most recent trading session. The 52-week high for ENTA is $17.15, which means the stock is currently trading -17.7% from its annual peak. The 52-week low is $4.09, putting the stock 245.0% above its annual trough. Recent trading volume was 228K shares, suggesting relatively thin trading activity.
Is ENTA Overvalued or Undervalued? — Valuation Analysis
ENANTA PHARMACEUTICALS INC (ENTA) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.08x, versus the sector average of 2.75x. The price-to-sales ratio is 5.66x, compared to 1.66x for the average Healthcare stock.
At current multiples, ENANTA PHARMACEUTICALS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
ENANTA PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score
ENANTA PHARMACEUTICALS INC (ENTA) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -59.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -22.8% versus the sector average of -33.1%.
On a margin basis, ENANTA PHARMACEUTICALS INC reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -116.7% (sector: -66.1%). Net profit margin stands at -111.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ENTA Debt, Balance Sheet, and Financial Health
ENANTA PHARMACEUTICALS INC has a debt-to-equity ratio of 160.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 4.44x, indicating strong short-term liquidity.
ENTA has a beta of 0.95, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ENANTA PHARMACEUTICALS INC is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
ENANTA PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ENANTA PHARMACEUTICALS INC reported revenue of $69M and earnings per share (EPS) of $-0.42. Net income for the quarter was $-75M. Gross margin was 100.0%. Operating income came in at $-78M.
In Q1 2026, ENANTA PHARMACEUTICALS INC reported revenue of $19M and earnings per share (EPS) of $-0.42. Net income for the quarter was $-12M. Revenue grew 9.8% year-over-year compared to Q1 2025. Operating income came in at $-11M.
In FY 2025, ENANTA PHARMACEUTICALS INC reported revenue of $65M and earnings per share (EPS) of $-3.84. Net income for the quarter was $-82M. Revenue grew -3.4% year-over-year compared to FY 2024. Operating income came in at $-85M.
In Q3 2025, ENANTA PHARMACEUTICALS INC reported revenue of $18M and earnings per share (EPS) of $-0.85. Net income for the quarter was $-18M. Gross margin was 100.0%. Revenue grew 1.9% year-over-year compared to Q3 2024. Operating income came in at $-19M.
Over the past 8 quarters, ENANTA PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $18M to $69M. Investors analyzing ENTA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ENTA Dividend Yield and Income Analysis
ENANTA PHARMACEUTICALS INC (ENTA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ENTA Momentum and Technical Analysis Profile
ENANTA PHARMACEUTICALS INC (ENTA) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.
ENTA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ENANTA PHARMACEUTICALS INC (ENTA) ranks #436 out of 838 stocks based on the Blank Capital composite score. This places ENTA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ENTA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ENTA vs S&P 500 (SPY) comparison to assess how ENANTA PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.
ENTA Next Earnings Date
No upcoming earnings date has been announced for ENANTA PHARMACEUTICALS INC (ENTA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ENTA? — Investment Thesis Summary
The quantitative profile for ENANTA PHARMACEUTICALS INC suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.
In summary, ENANTA PHARMACEUTICALS INC (ENTA) earns a Reduce rating with a composite score of 37.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ENTA stock.
Related Resources for ENTA Investors
Explore more research and tools: ENTA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ENTA head-to-head with peers: ENTA vs AZN, ENTA vs SLGL, ENTA vs VMD.